• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

A New Phase in the Treatment of Alzheimers Disease is Expected to Begin in 2009 With the Launch of Drugs That Slow the Progression of the Disease - Alzhemed and Flurizan

Posted on: Thursday, 5 January 2006, 15:00 CST

Research and Markets (http://www.researchandmarkets.com/reports/c30185) has announced the addition of Alzheimers Disease - Beta Treatments on the Horizon to their offering.

Alzheimers patients remain poorly treated and are growing in number. Currently, cholinesterase inhibitors and the more recent NMDA-receptor antagonists provide only moderate and temporary symptomatic benefit. By the end of the decade, however, drugs with the ability to slow the rate of disease progression are expected to be launched - most notably, the first beta-amyloid modulators.

This report provides an overview of the epidemiology of Alzheimers disease across the seven major markets and its diagnosis and management. It includes an examination of the Alzheimers disease pipeline with clinical and commercial profiles of late-stage candidates. Seven market sales forecasts, commercial potential and research/clinical/commercial assessment of late-stage products to 2014 are provided. The report includes insight and commentary from qualitative interviews with Alzheimers disease opinion leaders in the US, Europe and Japan

The Alzheimers disease market is forecast to continue to expand significantly over the next ten years. Aided by growing elderly populations, successive product launches have seen global revenues grow at over 35% CAGR 200104.

A new phase in the treatment of Alzheimers disease is expected to begin in 2009 with the launch of drugs that slow the progression of the disease - Alzhemed and Flurizan. Once launched, however, these drugs may not have long before further generations of disease modifying drugs arrive, pushing sales of Alzhemed and Flurizan into decline from 2013.

Clinical trial design will be key to the success of many new products. Trial duration must be appropriate for the drugs mechanism of action. Furthermore, selection of individuals from Alzheimers disease subgroups or those more likely to get the disease, can lead to better efficacy demonstration and lower required recruitment numbers.

Reasons to Purchase

-- Understand concerns over efficacy of currently available therapies and the impact of this on AChEI use

-- Identify potential patient segments in Alzheimers Disease for key late-stage compounds and rank future products

-- Assess the global sales forecasts of currently marketed products and evaluate the impact of generic galantamine

Companies mentioned:

-- Pfizer/Eisai

-- Johnson & Johnson

-- Novartis

-- Forest

-- Eli Lilly

-- Sanofi-Aventis

-- Axonyx

-- Mindset

Topics covered include:

-- Patient Potential

-- Market Overview

-- Country Market Assessment

-- R&D Approach

-- Drug Pipeline Analysis

-- Beta-Amyloid Modulators - Late-Stage Pipeline Analysis & Forecasts

-- Acetylcholine Modulators - Late-Stage Pipeline Analysis and Forecasts

-- NMDA Modulators - Late-Stage Pipeline Analysis and Forecasts

-- Neuroprotectants - Late-Stage Pipeline Analysis and Forecasts

-- Other Drugs - Late-Stage Pipeline Analysis and Forecasts

-- Innovative Early-Stage Projects

-- Forecast Analysis

-- Commercial Impact and Lifecycle Management: Case Studies

For more information visit http://www.researchandmarkets.com/reports/c30185

Source: Business Wire

More News in this Category